title: Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
abstract: The long term effect of donor specific antibodies (DSA) detected by Luminex Single Antigen Bead (SAB) assay in the absence of a positive complement-dependant cytotoxicity (CDC) crossmatch is unclear. DSA at the time of transplant were determined retrospectively in 258 renal transplant recipients from 2003 to 2007 and their relationship with rejection and graft function prospectively evaluated. After a median of 5.6 years follow-up 9% of patients had antibody mediated rejection (AMR) (DSA 11/37 (30%), DSA-Neg 13/221 (6%), HR 6.6, p<0.001). Patients with anti-HLA class II (HR 6.1) or both class I+II (HR 10.1) DSA had the greatest risk for AMR. The Mean Fluorescent Intensity (MFI) of the DSA was significantly higher in patients with AMR than those with no rejection (p=0.006). Moreover, the strength of the antibody was shown to be important, with the risk of AMR significantly greater in those with DSA >8000 MFI than those with DSA <8000 MFI (HR 23, p<0.001). eGFR progressively declined in patients with DSA but was stable in those without DSA (35.7 ± 20.4 mls/min vs 48.5 ± 22.7) and composite patient and graft survival was significantly worse in those with class II (HR 2.9) or both class I+II (HR 3.7) but not class I DSA. Class II DSA alone, or in combination with class I DSA had the strongest association with graft loss and patient death. Patients with DSA not only have increased rates of acute AMR, but also chronic graft dysfunction, graft loss and death. Antibody burden quantified by SAB assay may identify patients at highest immunological risk and therefore influence patient management and improve long-term patient outcome.
authors.affiliation: Department of Clinical Immunology, PathWest, Royal Perth Hospital, University of Western Australia, Australia. Samantha.Fidler@health.wa.gov.au
authors.forename: Samantha J
authors.initials: SJ
authors.lastname: Fidler
authors.forename: Ashley B
authors.initials: AB
authors.lastname: Irish
authors.forename: Wai
authors.initials: W
authors.lastname: Lim
authors.forename: Paolo
authors.initials: P
authors.lastname: Ferrari
authors.forename: Campbell S
authors.initials: CS
authors.lastname: Witt
authors.forename: Frank T
authors.initials: FT
authors.lastname: Christiansen
mesh_terms: D000906:Antibodies / Q000276:immunology*; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000401:mortality*; D006085:Graft Survival / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D015395:Histocompatibility Antigens Class I
keywords: AMR; Antibody-mediated Rejection; BPAR; Biopsy Proven Acute Rejection; CDC; Calculated Panel Reactive Antibody; Chronic rejection; Complement Dependant Cytotoxicity; DGF; DSA; Delayed Graft Function; Donor Specific Antibodies; Donor specific antibody (DSA); HB-MFI; Highest bead MFI; Kidney transplant; MFI; Mean Fluorescence Intensity; SAB; Single Antigen Bead; cPRA